Whether growth hormone deficiency (GHD) and/or treatment in childhood and adolescence influences cognitive outcome in children with GHD or girls with Turner syndrome (TS) is controversial. Previous studies also suggest that quality of life (QoL) is reduced in adults with GHD, particularly in the areas of social isolation and fatigue. Baseline QoL scores were significantly lower in patients with GHD than in the general population of the same age, gender, and nationality. Unfortunately, few data are available describing QoL in children with GHD. TS is a genetic disorder characterized by short stature, gonadal dysgenesis, and a particular neurocognitive profile of normally developed language abilities (particularly verbal intelligence quotients) and impaired visual-spatial and/or visual-perceptual abilities. This study evaluated the effects of GH treatment on neurocognitive function in girls with TS who were enrolled in a long-term, double-blind, placebo-controlled trial of the effects of GH treatment on final adult height. Treatment duration ranged from 1 to 7 years. The major result of this study was the absence of GH treatment effects on cognitive function in girls with TS. GHD and/or treatment in childhood and adulthood influences cognitive and/or QoL outcomes in some but not all studies. This study did not support a role for GH in influencing the characteristic nonverbal neurocognitive deficits associated with TS. However, evaluation of QoL should be a part of the routine clinical management of patients with GHD or TS.

Johansson JO, Larson G, Andersson M, Elmgren A, Hynsjo L, Lindahl A, Lundberg PA, Isaksson OG, Lindstedt S, Bengtsson BA: Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters. Neuroendocrinology 1995;61:57–66.
Lai Z, Roos P, Zhai O, Olsson Y, Fholenhag K, Larsson C, Nyberg F: Age-related reduction of human growth hormone-binding sites in the human brain. Brain Res 1993;621:260–266.
Burman P, Hetta J, Wide L, Mansson JE, Ekman R, Karlsson FA: Growth hormone treatment affects brain neurotransmitters and thyroxine. Clin Endocrinol (Oxf) 1996;44:319– 324.
Gordon M, Crouthamel C, Post EM, Richman RA: Psychosocial aspects of constitutional short stature: social competence, behavior problems, self-esteem, and family functioning. J Pediatr 1982;101:477–480.
Meyer-Bahlburg HF, Feinman JA, MacGillivray MH, Aceto T Jr: Growth hormone deficiency, brain development, and intelligence. Am J Dis Child 1978;132:565–572.
Stabler B, Clopper RR, Siegel PT, Stoppani C, Compton PG, Underwood LE: Academic achievement and psychological adjustment in short children. The National Cooperative Growth Study. J Dev Behav Pediatr 1994;15:1–6.
Drotar D, Owens R, Gotthold J: Personality adjustment of children and adolescents with hypopituitarism. Child Psychiatry Hum Dev 1980;11:59–66.
Holmes CS, Thompson RG, Hayford JT: Factors related to grade retention in children with short stature. Child Care Health Dev 1984;10:199–210.
Sandberg D, Ognibene TC, Brook AE, Barrick C, Shine B, Grundner W: Academic outcomes among children and adolescents receiving growth hormone therapy. Children’s Health Care 1998;27:265–282.
Abbott D, Rotnem D, Genel M, Cohen DJ: Cognitive and emotional functioning in hypopituitary short-statured children. Schizophr Bull 1982;8:310–319.
Siegel PT, Hopwood HN: The Relationship of Academic Achievement and the Intellectual Functioning and Affective Conditions of Hypopituitary Children. Hillsdale, NJ, Erlbaum, 1986.
Baum HB, Katznelson L, Sherman JC, Biller BM, Hayden DL, Schoenfeld DA, Cannistraro KE, Klibanski A: Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1998;83:3184–3189.
Deijen JB, de Boer H, Blok GJ, van der Veen EA: Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology 1996;21:313–322.
McGauley GA: Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1989;356:70–72; discussion 73–74.
Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, Karlsson FA: Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80:3585–3590.
Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA: Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 1994;40:111–116.
Wiren L, Whalley D, McKenna S, Wilhelmsen L: Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis. Clin Endocrinol (Oxf) 2000;52:143–152.
Badia X, Lucas A, Sanmarti A, Roset M, Ulied A: One-year follow-up of quality of life in adults with untreated growth hormone deficiency. Clin Endocrinol (Oxf) 1998;49:765–771.
Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW, Erfurth EM, Webb SM, Ross RJ, Chihara K, Henrich G, Herschbach P, Attanasio AF: Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 2004;89:1684–1693.
Radcliffe DJ, Pliskin JS, Silvers JB, Cuttler L: Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics 2004;22:499–524.
Smith MO, Shaywitz SE, Shaywitz BA, Gertner JM, Raskin LA, Gelwan EM: Exogenous growth hormone levels predict attentional performance: a preliminary report. J Dev Behav Pediatr 1985;6:273–278.
Clopper R: Assessing the Effect of Replacement Hormone Treatment on Psychosocial and Psychosexual Behavior in Growth Hormone Deficient Individuals. New York, Springer-Verlag, 1990.
Takano K, Tanaka T, Saito T: Psychosocial adjustment in a large cohort of adults with growth hormone deficiency treated with growth hormone in childhood: summary of a questionnaire survey. Committee for the Study Group of Adult GH Deficiency. Acta Paediatr Suppl 1994;399:16–19; discussion 20.
Clopper RR, MacGillivray MH, Mazur T, Voorhess ML, Mills BJ: Post-treatment Follow-up of Growth Hormone Deficient Patients. Hillsdale, NJ, Lawrence Erlbaum, 1986.
Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D: The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998;83:107–116.
van Dam PS, Aleman A, de Vries WR, Deijen JB, van der Veen EA, de Haan EH, Koppeschaar HP: Growth hormone, insulin-like growth factor I and cognitive function in adults. Growth Horm IGF Res 2000;10(suppl B):S69–S73.
Almqvist O, Thoren M, Saaf M, Eriksson O: Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. Psychoneuroendocrinology 1986;11:347–352.
Bjork S, Jonsson B, Westphal O, Levin JE: Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 1989;356:55–59; discussion 60, 73–54.
Sartorio A, Conti A, Molinari E, Riva G, Morabito F, Faglia G: Growth, growth hormone and cognitive functions. Horm Res 1996;45:23–29.
Oertel H, Schneider HJ, Stalla GK, Holsboer F, Zihl J: The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. Psychoneuroendocrinology 2004;29:839–850.
Svensson J, Mattsson A, Rosen T, Wiren L, Johannsson G, Bengtsson BA, Koltowska Haggstrom M, Swedish KIMS National Board: Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm IGF Res 2004;14:207–215.
Gilchrist FJ, Murray RD, Shalet SM: The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf) 2002;57:363–370.
Stouthart PJ, Deijen JB, Roffel M, Delemarre-van de Waal HA: Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinology 2003;28:612–626.
Ross JL, Stefanatos G, Roeltgen D, Kushner H, Cutler GB Jr: Ullrich-Turner syndrome: neurodevelopmental changes from childhood through adolescence. Am J Med Genet 1995;58:74–82.
Rovet J, Holland J: Psychological aspects of the Canadian randomized controlled trial of human growth hormone and low-dose ethinyl oestradiol in children with Turner syndrome. The Canadian Growth Hormone Advisory Group. Horm Res 1993;39(suppl 2):60–64.
Rovet J, Ireland L: Behavioral phenotype in children with Turner syndrome. J Pediatr Psychol 1994;19:779–790.
Rovet JF: The cognitive and neuropsychological characteristics of females with Turner syndrome; in Bender B, Berch D (eds): Sex Chromosome Abnormalities and Behavior: Psychological Studies. Boulder, Westview Press, 1991, pp 39–77.
Waber D: Neuropsychological aspects of Turner syndrome. Develop Med Child Neurol 1979;21:58–70.
Bender B, Puck M, Salbenblatt J, Robinson A: Cognitive development of unselected girls with complete and partial X monosomy. Pediatrics 1984;73:175–182.
Rovet JF: The psychoeducational characteristics of children with Turner syndrome. J Learn Disabil 1993;26:333–341.
Ross JL, McCauley E, Roeltgen D, Long L, Kushner H, Feuillan P, Cutler GB Jr: Self-concept and behavior in adolescent girls with Turner syndrome: potential estrogen effects [published erratum appears in J Clin Endocrinol Metab 1996;81:2191]. J Clin Endocrinol Metab 1996;81:926–931.
McCauley E, Kay T, Ito J, Treder R: The Turner syndrome: cognitive deficits, affective discrimination, and behavior problems. Child Develop 1987;58:464–473.
Collaer ML, Geffner ME, Kaufman FR, Buckingham B, Hines M: Cognitive and behavioral characteristics of Turner syndrome: exploring a role for ovarian hormones in female sexual differentiation. Horm Behav 2002;41:139–155.
Ross J, Zinn A, McCauley E: Neurodevelopmental and psychosocial aspects of Turner syndrome. Ment Retard Dev Disabil Res Rev 2000;6:135–141.
Ross JL, Feuillan P, Kushner H, Roeltgen D, Cutler GB Jr: Absence of growth hormone effects on cognitive function in girls with Turner syndrome. J Clin Endocrinol Metab 1997;82:1814–1817.
Weinberg WA, Dietz SG, Penick EC, McAlister WH: Intelligence, reading achievement, physical size and social class. A study of St. Louis Caucasian boys aged 8–0 to 9–6 years, attending regular schools. J Pediatr 1974;85:482–489.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.